3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Uterine Cervical Neoplasms
1
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
131
Cetuximab
80
Radiotherapy
76
Docetaxel
59
Carboplatin
46
pembrolizumab
45
Paclitaxel
44
Fluorouracil
42
Radiotherapy, Intensity-Modulated
35
Drug Therapy
17
Radiation
14
Nivolumab
14
Gefitinib
14
Gemcitabine
13
Surgical Procedures, Operative
12
Oxaliplatin
11
Erlotinib Hydrochloride
11
130-nm albumin-bound paclitaxel
11
Pemetrexed
10
Celecoxib
10
Capecitabine
10
Bevacizumab
10
tislelizumab
9
Filgrastim
9
Amifostine
9
Albumin-Bound Paclitaxel
9
durvalumab
7
atezolizumab
7
Chemoradiotherapy
7
toripalimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Head and Neck Neoplasms
×
DMAC2L protein, human
×
Clear all
NCT02748707
2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2
Unknown
64 enrolled